Amicus Therapeutics Inc. (Nasdaq: FOLD) reported positive results from a Phase 3 study of its Fabry disease treatment migalastat. Shares of the biopharmaceutical soared 93 cents to close at $5.50.
Positive study results from Amicus Therapeutics
August 20, 2014 at 09:27 AM EDT
